ArticleClinical ophthalmology (Auckland, N.Z.)2026
Long-Term Safety and Effectiveness of STREAMLINE Canaloplasty with Phacoemulsification in a Hispanic Population with Open-Angle Glaucoma.
Article in Clinical ophthalmology (Auckland, N.Z.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To report long-term clinical outcomes from a multicenter study evaluating STREAMLINE® Surgical System (STREAMLINE) canaloplasty, a minimally invasive glaucoma surgery (MIGS), combined with phacoemulsification in eyes with mild to moderate open-angle glaucoma (OAG). Design: Retrospective extension of a prospective, multicenter, interventional study. Participants: Participants were those in the original study who provided consent for retrospective long-term data collection. Methods: All eyes in this single-arm, retrospective extension study underwent STREAMLINE canaloplasty performed in combination with phacoemulsification between November 2021 and April 2022 at two sites in Latin America. Main Outcome Measures: The primary effectiveness outcome was the reduction in mean intraocular pressure (IOP) from Screening to last follow-up. Secondary effectiveness outcomes included mean change in topical IOP-lowering medication count from Screening compared to last follow-up. Safety assessments included visual acuity, visual field mean deviation, and incidence of adverse events (AEs). Results: Participants (n=28) at 2 of the 3 sites in the original study (n=43, 65.1%) consented to have retrospective data collected as part of this extension study. Average length of follow-up was 24.2±4.4 months (M24). Mean IOP (17.1±3.0 mmHg) and IOP-lowering medication count (1.86±0.80) at Screening decreased to 15.13±3.25 mmHg (p=0.002) and 0.54±1.17 (p<0.001), respectively. At M24, 92.9% of eyes were on the same or fewer medications compared to screening and 78.6% were medication free. No AEs were reported in the extension study (M12 to last follow-up). Conclusions: Canaloplasty with the STREAMLINE® Surgical System in combination with phacoemulsification provides clinically and statistically significant reduction in both IOP and the need for IOP-lowering medications in eyes with mild-moderate OAG in a Hispanic adult population through an average of 24 months post-operatively.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.